1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,072 | 1,082 | 02.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GENOMTEC Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INMODE | 11,675 | -2,30 % | InMode Ltd.: InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million | YOKNEAM, Israel, Feb. 10, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,060 | +6,69 % | Ryman Healthcare Slid To Loss In H1 | WELLINGTON (dpa-AFX) - Ryman Healthcare Ltd. (RYM.NZ), a retirement village and rest home operator, on Thursday reported loss in the first half compared with the previous year. For the half... ► Artikel lesen | |
| TANDEM DIABETES | 16,060 | -0,56 % | Truist upgrades Tandem Diabetes Care stock rating on Pay/Go model | ||
| JD HEALTH INTERNATIONAL | 5,300 | -3,64 % | JD Health Grants 0.8344 Million Award Shares | ||
| RADNET | 47,800 | +0,42 % | RadNet, Inc.: RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA?? and Releases 2026 Financial Guidance | Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable... ► Artikel lesen | |
| STAAR SURGICAL | 16,410 | +1,99 % | Alcon nach gescheiterter Staar-Übernahme: Beim Preis «diszipliniert» geblieben | Vernier - Alcon will nach der gescheiterten Übernahme von Staar Surgical die Strategie im Bereich Refraktionschirurgie beibehalten. Letztendlich wollte der Genfer Augenheilkunde-Konzern beim Preis keine... ► Artikel lesen | |
| TRANSMEDICS GROUP | 87,02 | -0,32 % | TransMedics Group, Inc.: TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results | ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant... ► Artikel lesen | |
| MEDACTA | 165,40 | 0,00 % | Medacta Group SA: Medacta selected as partner for groundbreaking international research project | Medacta Group SA
/ Key word(s): Miscellaneous
Medacta selected as partner for groundbreaking international research project
01.04.2026 / 06:00 CET/CEST
Media Release ... ► Artikel lesen | |
| DYNAVOX GROUP | 7,890 | -1,56 % | Dynavox Group has completed the acquisition of SR Labs Healthcare in Italy | ||
| INTERPACE BIOSCIENCES | 1,620 | 0,00 % | Interpace Biosciences, Inc.: Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results | Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4... ► Artikel lesen | |
| AVANOS MEDICAL | 12,200 | +0,83 % | Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2025 Results | Exceeded full-year revenue and achieved the top end of full-year earnings-per-share guidance
Delivered full-year organic growth of 6% in strategic segments
Expanded... ► Artikel lesen | |
| CHECK-CAP | 1,200 | -24,53 % | Check-Cap Ltd - 6-K, Report of foreign issuer | ||
| VIVANI MEDICAL | 0,900 | -3,74 % | Vivani Medical, Inc.: Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under... ► Artikel lesen | |
| MICROPORT SCIENTIFIC | 1,000 | -0,99 % | MicroPort EP wins European approval for PFA catheter |
Das Unternehmen GENOMTEC SA kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,41 % bei einem Aktienkurs von 0,965 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENOMTEC SA finden Sie auf Wallstreet Online.